• Investors may be wondering whether Chemed, at around US$422 per share, still lines up with its underlying worth or if the recent price is out of step with fundamentals.
• Over the last month the stock is up 11.8%, even though the 1 year return sits at a 26.3% decline and the year to date return is roughly flat at a 0.4% decline.
• Recent coverage around Chemed has focused on its role in healthcare services and how investors are weighing that profile against a weaker 1 year share price performance. This mix of sector attention and a softer multi year return helps explain why some investors are reassessing the balance between risk and potential reward.
• Simply Wall St currently gives Chemed a valuation score of 5 out of 6, which raises questions about how different methods like DCF, multiples and asset based metrics line up today, and whether a broader view of the business can offer an even clearer read on value by the end of this review.

Approach 1: Chemed Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a business could be worth by projecting its future cash flows and discounting them back to today, so you can compare that value with the current share price.

For Chemed, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flow projections. The latest twelve month Free Cash Flow is about $385.0 million. For 2026, the projected Free Cash Flow is $320.5 million, and for 2027 it is $346.3 million, based on analyst inputs. Beyond that, Simply Wall St extrapolates further, with the ten year path reaching a projected $439.8 million in 2035, all in $.

Putting these projections together, the model arrives at an estimated intrinsic value of about $691 per share. Against a current share price around $422, this implies a 38.9% discount, which indicates Chemed is trading below this DCF based estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Chemed is undervalued by 38.9%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Approach 2: Chemed Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it ties what you pay directly to the earnings the business is already producing. It helps you see how many dollars of share price you are paying for each dollar of earnings today.

A “normal” or “fair” P/E tends to reflect what investors expect for future growth and how much risk they see in the business. Higher expected growth or lower perceived risk usually justify a higher P/E, while lower growth expectations or higher risk usually point to a lower P/E.

Chemed currently trades on a P/E of 21.48x. That sits below the Healthcare industry average of about 24.87x and well below the peer average of 48.29x. Simply Wall St’s Fair Ratio for Chemed is 23.51x, which is its proprietary take on what the P/E could be given factors like earnings growth, industry, profit margin, market cap and risk profile.

This Fair Ratio is more tailored than a simple comparison with peers or the sector, because it incorporates company specific characteristics rather than relying on broad group averages. With the Fair Ratio of 23.51x above the current P/E of 21.48x, this approach points to the shares being undervalued on earnings.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Chemed Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Chemed into a clear story that links its hospice and Roto Rooter businesses to specific forecasts for revenue, earnings and margins, translates that into a Fair Value, and then compares it with the current price. This helps you see, in real time as new earnings or news arrive, why one investor on the Community page might back a higher Fair Value closer to US$580 while another leans toward US$400, and decide which story you find more convincing.

Do you think there's more to the story for Chemed? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.